Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis

MADRIGAL PHARMACEUTICALS, INC.

2024-FY EPS reported -$21.90 revenue$180,133,000

Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.
Over 11,800 patients on Rezdiffra at year-end 2024; cash and marketable securities $931.3M.
Two-year open-label data in compensated MASH cirrhosis (F4c): mean 6.7 kPa liver stiffness reduction (VCTE), statistically significant vs baseline.
51% of F4c patients achieved ≥25% reduction in liver stiffness; safety profile consistent with prior trials.
MAESTRO-NASH OUTCOMES trial fully enrolled (data anticipated 2027); CHMP opinion expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.